MIT Engineers Reprogrammed Immune Cells to Fight Cancer
A new technique successfully treated tumors in mice by training natural killer cells to hunt specific diseased cells.
Updated on Oct. 13, 2026 in Cancer
Live Poll
Should medical research prioritize developing in-body cell reprogramming to lower healthcare costs and improve accessibility?
MIT engineers have developed a method to reprogram natural killer cells directly inside a patient's body using messenger RNA. This approach, which successfully treated cancer and autoimmune hepatitis in mouse models, could provide a faster alternative to traditional cell therapies.
Why it matters
This technique aims to bypass the lengthy and costly manufacturing process of creating engineered cells outside the body. It represents a potential shift in how clinicians might address complex cancers and autoimmune conditions in the future.
In a preclinical study, MIT researchers used lipid nanoparticles to deliver mRNA to natural killer (NK) cells. The technique achieved 80% reprogramming efficiency in mice, leading to complete tumor remission in some subjects and successful treatment of autoimmune hepatitis.
The players
MIT
A research university that serves as a leader in bioengineering and the development of nanomedicine technologies.
Sanofi
A global pharmaceutical company that provided funding for the research and focuses on developing new therapies for cancer and immunological diseases.
National Cancer Institute
A federal agency that supports cancer research and funded this investigation into new immune-based treatment modalities.
The details
The system utilizes lipid nanoparticles coated with antibody fragments to target receptors on the surface of NK cells. Once attached, these nanoparticles deliver mRNA that encodes chimeric antigen receptors, effectively turning the NK cells into disease-fighting agents. In experimental models, this approach prompted the immune cells to identify and destroy dysfunctional T cells, clearing tumors in cases of T cell lymphoma.
Timeline
The findings were published on October 13, 2026, in the journal Nature Biotechnology.
Health Landscape
The medical community currently relies on seven FDA-approved CAR T cell treatments that require complex, lab-based manufacturing. This research suggests a future where in-body cellular reprogramming could bypass these significant logistical and financial hurdles.
This development is currently limited to preclinical research and is not available as a treatment option for patients. Discuss the status of emerging immunotherapies with your oncologist if you are tracking new developments in cancer care.
The takeaway
This technique offers a promising, less invasive path for immune-based cancer treatments. Patients should remain informed by following updates on clinical trial progress through major medical research institutions.
Further reading
Learn more about the latest research and standard clinical approaches in our Cancer section.
Live Poll
Should medical research prioritize developing in-body cell reprogramming to lower healthcare costs and improve accessibility?
